Soligenix reports Phase IIa SGX945 trial data for Behçet’s disease
SGX945 was well-tolerated with no treatment-related adverse events.
Clinical Trials
Qihan Biotech begins subject dosing in Phase I/IIa study of QT-019B for rSLE
Revealing the human and business cost of clinical trial inefficiencies for Data Managers and CRAs
Hutchmed begins Phase I HMPL-A251 clinical development programme
Northwell Health and START open early-phase cancer trial facility
Affibody’s ABY-271 breast cancer trial cleared to progress to next phase
First patient treated in trial of Beacon Therapeutics’ XLRP treatment
Kenai doses first patient in Phase I trial of cell therapy for Parkinson’s
